Regulation of Medical Devices in Spain by AEMPS

Regulatory Framework

Medical devices in Spain are regulated primarily through EU Regulations (EU) 2017/745 (MDR) and (EU) 2017/746 (IVDR), which have applied directly since May 2021 and May 2022 respectively, supplemented by national provisions where relevant. AEMPS (Agencia Española de Medicamentos y Productos Sanitarios) is the competent authority responsible for oversight, authorisation where required, vigilance, and enforcement. The framework is designed to ensure that devices meet the required safety and performance standards both before they enter the market and throughout their lifecycle. Productos sanitarios - AEMPS

Key Responsibilities of AEMPS

AEMPS plays a central role in the lifecycle management of medical devices in Spain. Its responsibilities are not limited to initial market access; they also extend to post-market supervision and regulatory enforcement.

• Conformity Assessment and CE Marking: Manufacturers must demonstrate compliance with applicable requirements through the appropriate conformity assessment route. For higher-risk devices, the involvement of a notified body is generally required. AEMPS oversees the national system and supervises notified bodies operating in Spain.
• Registration and Database Oversight: Devices placed on the market must be appropriately registered through the EU framework, with EUDAMED serving as the central database. During transitional periods, and in certain national scenarios, additional Spanish registration steps may still apply.
• Vigilance and Incident Reporting: AEMPS receives and coordinates the assessment of serious incident reports and field safety corrective actions. This function is critical for identifying trends, preventing recurrence, and ensuring that corrective actions are communicated effectively to all stakeholders.
• Market Surveillance and Enforcement: AEMPS may conduct inspections, request documentation, sample products, and verify whether devices remain compliant after market placement. Where non-compliance is identified, it can take corrective measures, including restrictions, withdrawals, or other enforcement actions.
• Clinical Investigation Oversight: For devices subject to clinical investigation, especially higher-risk products, AEMPS is involved in the review and authorisation process, ensuring that clinical evidence is ethically and scientifically robust.

Classification and Requirements

Devices are classified from Class I (lowest risk) to Class III (highest risk) under the MDR, and from Class A to D under the IVDR. As the classification increases, the regulatory burden becomes more demanding, particularly in relation to clinical evidence, technical documentation, and notified body involvement. Spain applies the harmonised EU framework, while AEMPS provides national guidance and administrative procedures to support implementation.

Practical Implications for Manufacturers

For manufacturers, the Spanish framework has several practical consequences that should be addressed early in the development and market-entry process.

First, manufacturers must determine the correct device classification at an early stage, because classification affects the conformity assessment route, the level of clinical evidence required, and the timeline to market. A misclassification can delay approval and create compliance risks.

Second, manufacturers established outside the EU must appoint an authorised representative within the Union. This is not merely a formal requirement: the authorised representative often becomes the main regulatory contact point for AEMPS and may be involved in vigilance communications, post-market documentation, and traceability matters.

Third, manufacturers should maintain a complete technical file and post-market documentation that can withstand regulatory scrutiny. AEMPS may request evidence relating to risk management, clinical evaluation, labelling, instructions for use, and post-market surveillance activities. Documentation should therefore be prepared in a way that supports both market access and inspection readiness.

Fourth, vigilance obligations require practical internal procedures. Manufacturers need systems for receiving and assessing complaints, identifying reportable incidents, implementing field safety corrective actions, and documenting communications with distributors, importers, and healthcare users. A delayed or incomplete response to an incident can create significant regulatory exposure.

Fifth, manufacturers should coordinate carefully with importers and distributors. Although AEMPS places primary responsibility on the manufacturer for conformity, downstream economic operators also have traceability and cooperation duties. Clear agreements on complaint handling, product recalls, and information flow are essential.

Finally, manufacturers should plan for Spanish-language and country-specific administrative expectations. Even where EU rules are harmonised, local operational requirements, communication practices, and documentary expectations may affect how smoothly a product is launched and maintained in the Spanish market.

Compliance Strategy

A robust compliance strategy for Spain should include regulatory classification review, CE conformity planning, technical documentation control, vigilance procedures, and ongoing market surveillance readiness. For many manufacturers, the most efficient approach is to integrate Spanish requirements into a broader EU regulatory strategy rather than treating Spain as a standalone market.

Conclusion

AEMPS functions as both a gatekeeper and a post-market supervisor within Spain’s medical device framework. For manufacturers, compliance is not only about obtaining access to the market, but also about maintaining traceability, documentation quality, and responsiveness throughout the product lifecycle. The most successful market entrants are those that treat regulatory planning as an ongoing operational obligation rather than a one-time approval step. Detailed information, forms, and guidance are available on the AEMPS website. Productos sanitarios - AEMPS